Prostate Cancer Medications

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Casodex is an androgen receptor inhibitor approved for metastatic prostate cancer.

Erleada is an androgen receptor inhibitor approved for nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration resistant).

Eulexin is an anti-androgen drug approved for locally confined metastatic prostate cancer.

Firmagon is a GnRH receptor blocker approved for advanced prostate cancer.

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

Orgovyx is a GnRH agonist approved for the treatment of people with advanced prostate cancer. It is the first oral medication in its class.

Nilandron is an anti-androgen drug used to treat men with metastatic prostate cancer after surgical castration, or removal of the testicles.

Nubeqa is an androgen receptor inhibitor approved for the treatment of nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant).

Trelstar is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

Xtandi is an androgen receptor inhibitor approved for metastatic or nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant), as well as cancer that remains sensitive to testosterone-blocking therapy.

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).

Lynparza is a PARP inhibitor approved for the treatment of advanced ovarian cancer in previously treated people with harmful BRCA mutations, maintenance treatment of ovarian cancer in people responding to chemotherapy, previously treated HER2-negative metastatic breast cancer in people with BRCA mutations, maintenance treatment of pancreatic cancer in people with BRCA mutations and previously treated metastatic castration-resistant prostate cancer in people with BRCA or other faulty DNA repair mutations.

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

Rubraca is a PARP inhibitor approved for maintenance treatment of people with recurrent ovarian, fallopian tube or primary peritoneal cancer that is responding to chemotherapy, for previously treated ovarian cancer in patients with harmful BRCA mutations and for previously treated metastatic castration-resistant prostate cancer in people with harmful BRCA mutations.

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.